ClinicalTrials.gg
RecruitingNCT05394142SPIOMET4HEALTHUpdated Apr 22, 2024

A Clinical Trial to Evaluate the Efficacy, Tolerability, and Safety of a Fixed Dose Combination of Spironolactone, Pioglitazone & Metformin (SPIOMET) in Polycystic Ovary Syndrome (PCOS)

A Phase 2 interventional study of Placebo and Pioglitazone in Polycystic Ovary Syndrome (PCOS), sponsored by Fundació Sant Joan de Déu. Recruiting at 7 sites in 6 countries. Open to female participants aged 12 Years to 23 Years. Per ClinicalTrials.gov, last updated 2024-04-22.

Sponsored by Fundació Sant Joan de Déu · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Started May 2022; still recruiting 4 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
364
Allocation
Randomized
Ages
12 Years to 23 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Polycystic Ovary Syndrome with a site in Spain — 3 open to participants now, 3 under way, none of them phase 3. Polycystic Ovary Syndrome · Spain.

Planned enrollment
Largest of 10
364 · median 50
Started
2022
the only one that year
Phase 2
Only one
of the 14
Registered
12th of 14
by date
Lead sponsor
1 of 14
Fundació Sant Joan de Déu

Among the 14 studies in Polycystic Ovary Syndrome with a site in Spain, this one has the largest planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2022, is the only one in phase 2, and was the 12th registered.

Polycystic Ovary Syndrome

959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.

Browse Polycystic Ovary Syndrome studies →

Open to participants now

3 of the 14 studies in Polycystic Ovary Syndrome with a site in Spain are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 120 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 106 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.

This study: 12 Years to 23 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Polycystic Ovary Syndrome with a site in Spain, or all of them as a file.
02

Study summary

This is a multi-centre, multi-national, double-blinded, placebo-controlled, parallel, randomised Phase II clinical trial to evaluate the efficacy, tolerability, and safety of a fixed dose combination of Spironolactone, Pioglitazone and Metformin (SPIOMET) for adolescent girls and young adult women with polycystic ovary syndrome.

Study description: Currently, there is no European Medicines Agency /U.S. Food and Drug Administration (FDA)-approved therapy for polycystic ovary syndrome in adolescent girls and young adult women. Oral contraceptives (OCs) are prescribed off-label to approximately 98% of AYAs with PCOS, including those without pregnancy risk. OCs alleviate key symptoms by inducing a pharmacological combination of anovulatory subfertility, regular pseudo-menses, and extreme elevations of sex hormone-binding globulin (SHBG), but OCs do not revert the underlying pathophysiology, and patients remain at risk for post-treatment subfertility and possibly, for lifelong co-morbidities.

Given the key role of hepato-visceral fat excess in the pathogenesis of PCOS, the prime aim of the treatment should be to achieve a preferential loss of central fat, which should in turn normalise the entire PCOS phenotype. Recent evidence disclosed that a treatment consisting of a fixed low-dose combination of two insulin sensitisers [pioglitazone (PIO) and metformin (MET), with different modes of action], and one mixed anti-androgen and anti-mineralocorticoid (spironolactone), was superior to an OC in normalising the PCOS phenotype, including ovulation rates and hepato-visceral fat.

The study's main goals are to assess the efficacy, tolerability and safety of a new treatment (SPIOMET) for adolescent girls and young adult women with polycistic ovarian syndrome; the comparison (in this order) of each SPIOMET, spironolactone and pioglitazone (SPIO) and PIO over placebo; and in addition, the comparison of SPIOMET over PIO and over SPIO (in this order).

Primary Objective: To test the efficacy of SPIOMET in normalising ovulation rate in adolescents and young adult women with PCOS.

Secondary Objectives: To test the efficacy of SPIOMET in normalising the endocrine-metabolic status, to describe the drug safety profile and to assess the adherence and subjective acceptability, as well as the quality of life of the participating subjects.

Read the detailed description

This is a multi-centre, multi-national, double-blinded, placebo-controlled, parallel, randomised Phase II clinical trial to evaluate the efficacy, tolerability, and safety of a fixed dose combination of Spironolactone, Pioglitazone and Metformin (SPIOMET) for adolescent girls and young adult women (AYAs) with polycystic ovary syndrome (PCOS).

Study description: Currently, there is no European Medicines Agency (EMA)/U.S. Food and Drug Administration (FDA)-approved therapy for PCOS in AYAs. Oral contraceptives (OCs) are prescribed off-label to approximately 98% of AYAs with PCOS, including those without pregnancy risk. OCs alleviate key symptoms by inducing a pharmacological combination of anovulatory subfertility, regular pseudo-menses, and extreme elevations of sex hormone-binding globulin (SHBG), but OCs do not revert the underlying pathophysiology, and patients remain at risk for post-treatment subfertility and possibly, for lifelong co-morbidities.

Given the key role of hepato-visceral fat excess in the pathogenesis of PCOS, the prime aim of the treatment should be to achieve a preferential loss of central fat, which should in turn normalise the entire PCOS phenotype. Recent evidence disclosed that a treatment consisting of a fixed low-dose combination of two insulin sensitisers [pioglitazone (PIO) and metformin (MET), with different modes of action], and one mixed anti-androgen and anti-mineralocorticoid (spironolactone), was superior to an OC in normalising the PCOS phenotype, including ovulation rates and hepato-visceral fat.

03

Conditions studied

  • Polycystic Ovary Syndrome (PCOS)

Keywords

  • polycystic ovary syndrome
  • spironolactone
  • pioglitazone
  • metformin
  • peadiatric
  • PCOS
04

Who can participate

Ages eligible
12 Years to 23 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  1. Age range within the AYAs category (> 12.0 years and ≤ 23.9 years at study start) (96); Given that another inclusion criterium is gynaecological age (years elapsed since menarche) of 2 years or more, and that menarche before age 10.0 years is an exclusion criterium (please see exclusion criteria below), the youngest participant will be older than 12.0 years at study start (97). The upper age limit at study start is set at 23.9 years (thus, 24.9 years when the active treatment ends, see section 7. Conduct), in order to avoid early dropouts due to an increase in the prevalence of pregnancy wish beyond that age in most European countries;
  2. Gynaecological age of 2 years or more;
  3. Clinical androgen excess, as defined by the presence of hirsutism (modified Ferriman-Gallwey score ≥ 4) (17,98) and/or inflammatory acne (Leeds scale) unresponsive to medications (3,95,99). The scarce normative data existing in adolescents suggest that an adult level of hirsutism is reached around 2 years after menarche (100);
  4. Biochemical androgen excess, as defined by increased total testosterone (≥50 ng/dL), and/or a FAI higher than 3.5 [FAI, total testosterone (nmol/L) x 100/SHBG (nmol/L)], in the follicular phase of the cycle (days 3-7) or after 2 months of amenorrhea (3,100,101); Measurements of total testosterone and/or FAI are the most recommended assessments to screen for hyperandrogenaemia (3,19,95,102). Serum testosterone attains adult levels shortly after menarche; thus, an elevation of serum testosterone concentrations and/or FAI above adult norms and assessed in reliable reference laboratories constitutes biochemical evidence of hyperandrogenism (3,19,95,100). It is accepted that this upper limit can be set at 45 ng/dL for testosterone and at 3.5 for FAI (3,95,100,101,102,103). Direct free testosterone assays, such as radiometric or enzyme-linked assays, preferably should not be used in the assessment of biochemical hyperandrogenism, as they demonstrate poor sensitivity, accuracy and precision (17);
  5. Menstrual irregularity, as defined by ≤ 8 menses per year corresponding to an average inter-menstrual time of ≥45 days (3,95,100); Most adolescents establish a menstrual interval of 20-45 days within the first 2 years after menarche (3,95). Three years after menarche, the 95th percentile for cycle length is 43.6 days (104); thus, cycles longer than 45 days (\<8 periods/year) at or beyond this gynaecological age are considered abnormal and are evidence of oligo-anovulation;
  6. Written obtained from the patient, or assent from the patient and consent by the parents or the legally acceptable representative if she is a minor (for details, see section 7. Conduct, under informed consent).

Exclusion criteria

Exclusion Criteria:

-

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
364 participants (estimated)

Study arms

  • Placebo comparator
    Arm 1 - Placebo

    Placebo

    Drug: Placebo

  • Experimental
    Arm 1 - PIO

    Pioglitazone

    Drug: Pioglitazone

  • Experimental
    Arm 1 - SPIO

    Spironolactone and Pioglitazone

    Drug: Pioglitazone · Drug: Spironolactone

  • Experimental
    Arm 1 - SPIOMET

    Spironolactone, Pioglitazone and Metformin

    Drug: Pioglitazone · Drug: Spironolactone · Drug: Metformin

Interventions

  • DrugPlacebo

    Comparator arm with placebo

  • Pioglitazone 7.5 mg/day

    Also known as: PIO

  • Spironolactone 50 mg/day

    Also known as: S

  • Metformin 850 mg/day

    Also known as: MET

06

What researchers measure

Primary outcomes

  1. On-treatment ovulation rate.

    On-treatment ovulation rate.

    Time frame: Following end of each two 12-week on-treatment periods (month 0-3 and month 9-12)

  2. Post-treatment ovulation rate.

    Post-treatment ovulation rate.

    Time frame: Following the end of post-treatment period (month 12-15)

Secondary outcomes

  1. Clinical variable: hirsutism

    Presence of hirsutism as measured by the modified Ferriman \& Gallwey score

    Time frame: Every 3 months from study start to study completion (estimated 18 months)

  2. Clinical variable: Acne

    Presence of Acne as evaluated using the Leeds Acne Grading Scale

    Time frame: Every 3 months from study start to study completion (estimated 18 months)

  3. Clinical variable: menstrual regularity

    Assessment of the menstrual regularity

    Time frame: Every 3 months from study start to study completion (estimated 18 months)

  4. Circulating androgens

    Assessment by measurement of circulating androgens

    Time frame: Every 3 months from study start to study completion (estimated 18 months)

  5. Lipids

    Assessment by measurement of total cholesterol, low-density lipoprotein (LDL-cholesterol), high-density lipoprotein (HDL- cholesterol), triglycerides;

    Time frame: Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment

  6. Insulinaemia

    Fasting and 2 hours after a 75-gr oral glucose load \[oral glucose tolerance test (oGTT). Estimation of insulin resistance from fasting insulin and glucose levels using the homeostasis model assessment (HOMA);

    Time frame: Baseline and at the end of treatment (month 12) and 6 months after treatment

  7. Inflammation markers

    Inflammation markers

    Time frame: Baseline and at the end of treatment (month 12) and 6 months after treatment

  8. Insulin sensitivity

    Insulin sensitivity

    Time frame: Baseline and at the end of treatment (month 12) and 6 months after treatment

  9. Ultra-sensitive C-reactive protein (us-CRP);

    Ultra-sensitive C-reactive protein (us-CRP);

    Time frame: Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment

  10. Growth-and- differentiation factor-15 (GDF15);

    Growth-and- differentiation factor-15 (GDF15);

    Time frame: Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment

  11. High molecular weight adiponectin (HMW-adip),

    High molecular weight adiponectin (HMW-adip),

    Time frame: Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment

  12. C-X-C motif chemokine ligand 14 (CXCL14) (69,81);

    C-X-C motif chemokine ligand 14 (CXCL14) (69,81);

    Time frame: Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment

  13. Epigenetic variable

    Circulating microRNA 451-a (miR-451a) concentrations (88);

    Time frame: Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment

  14. Imaging: Cardiovascular risk

    As measured by ultrasound

    Time frame: Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment

  15. Imaging: Body composition

    As measured by dual-energy X-ray absorptiometry (DXA)

    Time frame: Baseline and at the end of treatment (month 12) and 6 months after treatment

  16. Imaging: Abdominal fat distribution (subcutaneous and visceral)

    As measured by MRI

    Time frame: Baseline and at the end of treatment (month 12) and 6 months after treatment

  17. Imaging:hepatic fat

    As measured by MRI

    Time frame: Baseline and at the end of treatment (month 12) and 6 months after treatment

  18. Abdominal fat distribution

    Waist circumference, Waist to hip ratio (WHR), and hepatic fat by MRI

    Time frame: Baseline and at the end of treatment (month 12) and 6 months after treatment

  19. Weight

    Weight measurement

    Time frame: Every 3 months from study start to study completion (estimated 18 months)

  20. Improvement of co-morbidities

    Improvement of co-morbidities

    Time frame: Every 3 months from study start to study completion (estimated 18 months)

  21. Improvement of health behaviour

    Improvement of health behaviour

    Time frame: Every 3 months from study start to study completion (estimated 18 months)

  22. Improvement of health-related quality of life (HRQoL)

    As reported by the patient

    Time frame: Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment

  23. Safety laboratory tests

    Blood count, electrolyte panel, urea, alanine transaminase (ALT), aspartate transaminase (AST), gamma-glutamyltransferase (GGT), creatinine, vitamin B12 and folic acid;

    Time frame: Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment

  24. Adverse events (AEs)

    As reported by the patient

    Time frame: Every 3 months from study start to study completion (estimated 18 months)

  25. Adherence

    Adherence will be calculated as the ratio between the number of tablets prescribed and dispensed for the period between hospital appointments and the number of tablets returned by the patient at the following appointment;

    Time frame: Every 3 months from study start to study completion (estimated 18 months)

  26. Acceptability of the treatment

    Acceptability of the tablet by the study patients

    Time frame: Every 3 months from study start to study completion (estimated 18 months)

  27. PROMs (patient-reported outcomes)

    Questionnaire SF-36

    Time frame: Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment

  28. PROMs (patient-reported outcomes)

    Questionnaire PCOSQ

    Time frame: Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment

  29. HRQoL (health-related quality of life)

    Questionnaire SF-36

    Time frame: Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment

  30. HRQoL (health-related quality of life)

    Questionnaire PCOSQ

    Time frame: Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment

07

Study locations

7 of 7 sites recruiting
  • Universitätsklinik für Innere Medizin
    Graz, Austria
    Recruiting
    • Barbara Obermayer-Pietsch · Contact
  • Odense University Hospital (UNIODE)
    Odense, Denmark
    Recruiting
    • Pernille Ravn · Contact
  • Azienda Ospedaliero Universitaria di Bologna
    Bologna, Italy
    Recruiting
    • Alessandra Gambineri · Contact
  • St. Olavs Hospital
    Trondheim, Norway
    Recruiting
    • Eszter Vanky · Contact
  • Hospital Sant Joan de Deu
    Esplugues De Llobregat, Spain
    Recruiting
    • Lourdes Ibañez · Contact
  • Hospital Universitari de Girona Dr. Trueta
    Girona, Spain
    Recruiting
    • Abel López Bermejo · Contact
  • İstanbul Faculty of Medicine Topkapı
    Istanbul, Turkey
    Recruiting
    • Feyza Darendeliler · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Apr 2025, 35 months after the start.

Of 23 phase 2 interventional studies under Polycystic Ovary Syndrome, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 29. This study's planned 35 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2022
First posted
May 27, 2022
StartActual
May 24, 2022
Primary completionEst.
Apr 2025
CompletionEst.
Apr 2025
Last update
Apr 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05394142
Lead sponsor
Fundació Sant Joan de Déu
Responsible party
Sponsor
First posted
May 27, 2022
Start date
May 24, 2022
Primary completion
Apr 2025 (estimated)
Completion
Apr 2025 (estimated)
Last update
Apr 22, 2024

Study contacts

Rita Malpique, PhD
Contact
rita.malpique@sjd.es
+34936 00 97 51 ext. 77806
Elizabeth García Pérez, PhD
Contact
+34936 00 97 51 ext. 77848
Lourdes Ibañez, MD, PhD
principal investigator · Investigator

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pioglitazone · Spironolactone · Metformin

Start the discussion